Treatment with TKIs, such as gefitinib and lapatinib, has been shown in vitro and in vivo to inhibit downstream effector pathway and proliferation of EGFR- and/or HER2-overexpressing ESCC [47,48]. Here, ERBB2 is linked to esophageal squamous cell carcinoma.